Full Breakdown
Rising Antibody Prevalence Suggests Broader Exposure to Alpha-Gal Syndrome in Lone Star Tick Regions
7/3/2026, 5:30:32 AM
New CDC Study Reveals High Alpha-Gal Antibody Prevalence
A CDC analysis of 3,000 adult blood samples collected Nov 2024–Apr 2025 in ten states found about 24 % of adults in Arkansas, Kentucky, Missouri, Tennessee and Virginia have alpha-gal antibodies, indicating prior tick exposure.
Tick-Borne Transmission and Emerging Risk
Lone-star ticks acquire alpha-gal when feeding on mammals such as cows, deer, goats and pigs and can transmit it to humans. Black-legged, Cayenne and Asian longhorned ticks also carry the sugar, widening risk.
Researchers and Advocacy Leaders
The study was led by Dr. Eleanor Saunders, infectious-disease specialist at UNC-Chapel Hill, with Dr. Scott Commins, allergy-immunology specialist at the same university, as co-author. Sharon Forsyth heads the nonprofit Alpha-Gal Alliance Action Fund. The CDC supplied the data.
Data Highlights & Public Health Impact
The analysis of 3,000 donors from ten states found 24 % antibody prevalence in five states and contrasts with the CDC’s estimate of about 450,000 syndrome cases nationwide. No state mandates reporting, and the condition is not on the national notifiable disease list. The high antibody rate suggests a larger at-risk population, while warming winters enable tick migration westward, potentially extending exposure. Alpha-gal syndrome remains lifelong.
Official Statements
CDC officials note that antibodies confirm exposure but do not diagnose the syndrome. Dr. Saunders warned that antibody presence alone does not indicate disease and cautioned against overdiagnosis. Dr. Commins noted rising cases in Oklahoma and Great Lakes region. The agency reaffirmed that alpha-gal syndrome remains outside National Notifiable Diseases Surveillance System.
Criticism of Surveillance Gaps
Sharon Forsyth called the lack of national tracking “mind-boggling” and “insane,” arguing that alpha-gal is among the most common vector-borne diseases in the United States yet remains uncounted.
Conflicting Estimates
The 24 % antibody rate in five states suggests higher exposure than the CDC’s estimate of 450,000 syndrome cases. It remains unclear what fraction of antibody-positive individuals will develop allergy, and the lack of mandatory reporting creates data gaps.
Verbatim Quotes
- “We are concerned about overdiagnosis.” — Dr. Eleanor Saunders, Infectious Disease Specialist, UNC-Chapel Hill
- “mind-boggling,” — Sharon Forsyth, Executive Director, Alpha-Gal Alliance Action Fund
- “There’s no doubt that alpha-gal is one of the most common vector-borne diseases in the United States, yet they’re not counting cases. How insane is that?” — Sharon Forsyth
- “We’re seeing an increase in cases in the Oklahoma region, and northward into the Great Lakes,” — Dr. Scott Commins, Allergy Immunology Specialist, UNC-Chapel Hill
Upcoming Steps
CDC and the Council of State and Territorial Epidemiologists will consider adding alpha-gal syndrome to the national notifiable disease list. Researchers plan longitudinal studies to assess risk among antibody-positive individuals, while public-health agencies monitor tick range expansion.
